RightFit Trial Directory

Lung Cancer clinical trials in New York, NY

99 recruiting lung cancer studies with a site in New York, NY.

All trials in New York, NY · All Lung Cancer trials

RecruitingPhase 3NCT03394365

A Phase 3 Study of Tabelecleucel for Participants With Epstein-Barr Virus-Associated Post-Transplant Lymphoproliferative Disease After Failure With Rituximab or Rituximab and Chemotherapy

Sponsor: Pierre Fabre Medicament

New York, NY · +37 more sites

RecruitingPhase 1 / Phase 2NCT04977453

GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors

Sponsor: GI Innovation, Inc.

New York, NY · +1 more sites

RecruitingPhase 1 / Phase 2NCT06162221

Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLC

Sponsor: Revolution Medicines, Inc.

New York, NY · +26 more sites

RecruitingPhase 1NCT06465069

A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors

Sponsor: Eli Lilly and Company

New York, NY · +20 more sites

RecruitingPhase 3NCT06623422

A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

Sponsor: Merck Sharp & Dohme LLC

Buffalo, NY · East Syracuse, NY · New York, NY · +51 more sites

RecruitingPhase 1 / Phase 2NCT06810544

Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss

Sponsor: Tango Therapeutics, Inc.

New York, NY · +13 more sites

RecruitingPhase 1 / Phase 2NCT07038343

AVENTINE-1: Study of AVZO-1418 as a Single Agent and in Combination Therapy in Patients With Locally Advanced or Metastatic Solid Tumors (AVZO-1418-1001)

Sponsor: Avenzo Therapeutics, Inc.

New York, NY · +18 more sites

RecruitingPhase 1 / Phase 2NCT07020221

A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors

Sponsor: Verastem, Inc.

New York, NY · +12 more sites

RecruitingPhase 3NCT06712355

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer

Sponsor: BioNTech SE

New York, NY · White Plains, NY · +34 more sites

RecruitingPhase 1 / Phase 2NCT05786924

Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies

Sponsor: Institut de Recherches Internationales Servier

New York, NY · +19 more sites

RecruitingNot applicableNCT06228209

Tier - Palliative Care For Patients With Advanced Heart Failure or Cancer

Sponsor: Icahn School of Medicine at Mount Sinai

New York, NY

RecruitingPhase 1NCT07094204

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

Sponsor: Astellas Pharma Inc

Buffalo, NY · New York, NY · +9 more sites

RecruitingPhase 3NCT07128199

A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Sponsor: Taiho Oncology, Inc.

Commack, NY · East White Plains, NY · Lake Success, NY · +27 more sites

RecruitingPhase 3NCT07410117

REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis

Sponsor: Regeneron Pharmaceuticals

New York, NY · +3 more sites

RecruitingPhase 2NCT06031688

Targeted Treatment for Advanced Non-Small Cell Lung Cancer That Has a MET Exon 14 Skipping Gene Change (An Expanded Lung-MAP Treatment Trial)

Sponsor: SWOG Cancer Research Network

Commack, NY · Cooperstown, NY · Harrison, NY · +275 more sites

RecruitingPhase 1 / Phase 2NCT07070232

A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

Sponsor: BioNTech SE

New York, NY · +18 more sites

RecruitingPhase 2 / Phase 3NCT07100080

Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)

Sponsor: Bristol-Myers Squibb

Mineola, NY · New York, NY · +25 more sites

RecruitingPhase 2NCT07476287

Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer

Sponsor: Pfizer

Commack, NY · Harrison, NY · Long Island City, NY · +20 more sites

RecruitingPhase not listedNCT07690917

A Study of a New PET Scanner in People With Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

Commack, NY · Harrison, NY · New York, NY · +4 more sites

RecruitingPhase 3NCT06119581

A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

Sponsor: Eli Lilly and Company

Brooklyn, NY · Lake Success, NY · Mineola, NY · +84 more sites

RecruitingPhase 3NCT06216301

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

Sponsor: NovoCure GmbH

New Hyde Park, NY · New York, NY · Rochester, NY · +35 more sites

RecruitingPhase 2NCT07492680

A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5)

Sponsor: Bristol-Myers Squibb

Buffalo, NY · New York, NY · +13 more sites

RecruitingNot applicableNCT06037954

A Study of Mental Health Care in People With Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

New York, NY

RecruitingPhase 1 / Phase 2NCT06060613

Safety and Efficacy of OBX-115 in Advanced Solid Tumors

Sponsor: Obsidian Therapeutics, Inc.

New York, NY · +8 more sites

RecruitingPhase 1NCT07164313

A Study of ZW251 in Participants With Advanced Solid Tumors

Sponsor: Zymeworks BC Inc.

New York, NY · +7 more sites

RecruitingPhase 1NCT07454642

AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors

Sponsor: Avacta Life Sciences Ltd

New York, NY · +6 more sites

RecruitingPhase 2NCT07293247

A Study of Targeted Post-Surgery Radiation Therapy for Non-Small Cell Lung Cancer With Remaining Lymph Node Cancer After Treatment

Sponsor: Alliance for Clinical Trials in Oncology

Commack, NY · Harrison, NY · New York, NY · +108 more sites

RecruitingPhase 2NCT06172478

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

Sponsor: Daiichi Sankyo

Buffalo, NY · New York, NY · +11 more sites

RecruitingPhase 1 / Phase 2NCT06362252

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

Sponsor: Daiichi Sankyo

Mineola, NY · New York, NY · +23 more sites

RecruitingPhase 3NCT07361497

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

Sponsor: Bristol-Myers Squibb

New York, NY · Westbury, NY · +35 more sites

RecruitingPhase 3NCT07361510

A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

Sponsor: Bristol-Myers Squibb

Laurelton, NY · New York, NY · Westbury, NY · +38 more sites

RecruitingPhase 1NCT05877599

A Study of NT-175 in Adult Participants With Advanced Malignancies That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation

Sponsor: AstraZeneca

New York, NY · +19 more sites

RecruitingPhase 1NCT07277413

A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors

Sponsor: IDEAYA Biosciences

New York, NY · +22 more sites

RecruitingPhase 1NCT06218914

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

Sponsor: AstraZeneca

New York, NY · +16 more sites

RecruitingPhase 1NCT07037758

A Study of Tarlatamab in Combination With AB248 in Participants With Extensive Stage Small Cell Lung Cancer (DeLLphi-311)

Sponsor: Amgen

New York, NY · +12 more sites

RecruitingNot applicableNCT06037941

Using E-Nose Technology to Measure Response to Treatment in People With Malignant Pleural Mesothelioma

Sponsor: Memorial Sloan Kettering Cancer Center

Commack, NY · Harrison, NY · New York, NY · +4 more sites

RecruitingPhase 3NCT06561386

A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%

Sponsor: Bristol-Myers Squibb

Hawthorne, NY · New York, NY · Northport, NY · +53 more sites

RecruitingNot applicableNCT07661966

Bright Light Therapy in Patients With Melanoma or Non-small Cell Lung Cancer (NSCLC) Who Are Receiving First-Line Immune Checkpoint Blockade

Sponsor: Weill Medical College of Cornell University

New York, NY

RecruitingPhase 1NCT06858813

A Study to Assess Adverse Events and Change in Disease Activity of Intravenously (IV) Infused ABBV-324 in Adult Participants With Hepatocellular Cancer (HCC) or Squamous-Cell Non-Small Cell Lung Cancer (LUSC)

Sponsor: AbbVie

New York, NY · +9 more sites

RecruitingPhase not listedNCT07174388

An External Control Arm Study in Non-Small Cell Lung Cancer

Sponsor: N-Power Medicine

New York, NY · +10 more sites

RecruitingPhase 1NCT05983432

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Sponsor: SystImmune Inc.

New York, NY · +21 more sites

RecruitingPhase 1 / Phase 2NCT07629960

A First-in-Human Trial of BLU-924 (SAR449336) in Advanced Solid Tumors Harboring KRAS Mutations

Sponsor: Blueprint Medicines Corporation

New York, NY · +9 more sites

RecruitingPhase 3NCT06767514

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1

Sponsor: Summit Therapeutics

New York, NY · Syracuse, NY · The Bronx, NY · +94 more sites

RecruitingPhase 2NCT06855771

A Study of Navlimetostat (BMS-986504) Alone or in Combination With Izalontamab Brengitecan in Participants With Pre-treated Advanced or Metastatic Non-small Cell Lung Cancer (NSCLC) With Homozygous MTAP Deletion or MTAP Loss (MountainTAP-9)

Sponsor: Bristol-Myers Squibb

New York, NY · +9 more sites

RecruitingPhase 1NCT07020117

A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors

Sponsor: Aktis Oncology, Inc.

New York, NY · +12 more sites

RecruitingPhase 1NCT07080242

Evaluating BL-M14D1 in Subjects With Locally Advanced or Metastatic Small Cell Lung Cancer and Neuroendocrine Tumors

Sponsor: SystImmune Inc.

New York, NY · +23 more sites

RecruitingPhase not listedNCT06033248

Using Urine Samples to Identify Lung Cancer

Sponsor: Memorial Sloan Kettering Cancer Center

Commack, NY · Harrison, NY · New York, NY · +4 more sites

RecruitingPhase 2NCT07002034

RE104 Safety and Efficacy Study in Adjustment Disorder in Cancer and Other Medical Illnesses

Sponsor: Reunion Neuroscience Inc

Buffalo, NY · New York, NY · +30 more sites

RecruitingPhase 1NCT07217171

A Study Evaluating the Safety, Efficacy, and Pharmacokinetics (PK) of EVOLVE104 in Participants With Advanced Urothelial and Squamous Cell Carcinomas

Sponsor: EvolveImmune United, Inc

New York, NY · +13 more sites

RecruitingPhase not listedNCT05059444

ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation

Sponsor: Guardant Health, Inc.

New York, NY · +32 more sites

Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.